Antibiotic therapy for severe bacterial infections: Correlation between the inhibitory quotient and outcome

International Journal of Antimicrobial Agents

Volumn 23, Issue 2, 2004, Pages 120-128

  Spanu, Teresa ^a   Santangelo, Rosaria ^a   Andreotti, Felicita ^a   Cascio, Giuliana Lo ^a   Velardi, Giuseppe ^a   Fadda, Giovanni ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Antimicrobial therapy; Inhibitory quotient; Therapeutic outcome

Indexed keywords

AMIKACIN; AMPICILLIN; ANTIBIOTIC AGENT; AZTREONAM; CEFOPERAZONE; CEFOTETAN; CEFTAZIDIME; CEFTIZOXIME; CEFTRIAXONE; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; PEFLOXACIN; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN; TOBRAMYCIN; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; CHOLANGITIS; CITROBACTER FREUNDII; COMMUNITY ACQUIRED PNEUMONIA; CORRELATION ANALYSIS; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MALE; MULTIVARIATE ANALYSIS; PNEUMONIA; PREDICTION; PRIMARY INFECTION; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0842307143     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2003.06.006     Document Type: Article

References (44)

1. Lorian V., Burns L. Predictive value of susceptibility tests for the outcome of antibacterial therapy. J. Antimicrob. Chemother. 25:1990;175-181.
2. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Ninth informational supplement, M100-S9. Wayne, PA: NCCLS; 1999.
3. National Committee for Clinical Laboratory Standards. Performance Standards for antimicrobial susceptibility testing M7-A5. Wayne, PA: NCCLS; 2000.
4. Hilf M., Yu V.L., Sharp J., Zuravleff J.J., Korvich J.A., Murder R.R. Antibiotic therapy for Pseudomonas aeruginosa bacteraemia: outcome correlations in a prospective study of 200 patients. Am. J. Med. 87:1989;540-546.
5. Forrest A., Nix D.E., Ballow C.H., Goss T.F., Birmingham M.C., Schentag J.J. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37:1993;1073-1081.
6. Garraffo R. Optimal adaptive control of pharmacodynamic effects with aminoglycoside antibiotics: a required approach for the future. Int. J. Biomed. Comput. 36:1994;43-57.
7. Neu H.C. Clinical microbiology of azithromycin. Am. J. Med. 91:1991;12-18.
8. Scaglione F. Predicting the clinical efficacy of antibiotics: toward definitive criteria. Pediatr. Infect. Dis. J. 16:1997;56-59.
9. Hindler J. Antimicrobial susceptibility testing. In: Isenberg HD, editor. Clinical microbiology procedures handbook. Washington: American Society for Microbiology; 1992.
10. Scholar EM, Pratt WB, editors. The antimicrobial drugs. 2nd ed. Oxford: Oxford University Press; 2000.
11. Ellner P.D., Neu H.C. The inhibitory quotient, a method for interpreting MIC data. JAMA. 246:1981;1575-1578.
12. Neu H.C., Ellner P.D. The inhibitory quotient. Bull. N.Y. Acad. Med. 59:1983;430-442.
13. Mandell G, Douglas RG, Bennett JE, editors. Principles and practice of infectious diseases. 3rd ed. New York: Churchill Livingstone; 1990.
14. Garner J.S., Jarvis W.R., Emori T.G., Horan T.C., Hughes J.M. CDC definitions for nosocomial infections. Am. J. Infect. Contr. 16:1988;128-140. [Erratum, 16:177].
15. Trouillet J.L., Chastre J., Vuagnat A., Joly-Iuillou M.L., Combaux D., Dombret M.C., Gilbert C. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am. J. Respir. Crit. Care Med. 157:1998;531-539.
16. Isenberg HD, editor. Clinical microbiology procedures handbook. Washington: American Society for Microbiology; 1992.
17. Lorian V, editor. Antibiotics in laboratory medicine. Baltimore: Williams & Williams; 1988.
18. Bassi C., Pederzoli P., Vesentini S., Falconi M., Bonora A., Abbos H., Benini A., Bertazzoni E.M. Behaviour of antibiotics during human necrotizing pancreatitis. Antimicrob. Agents Chemother. 38:1994;830-836.
19. SAS Institute Inc. SAS user's guide. Cary, NC: SAS Institute Inc.; 1990.
20. Knaus W.A., Wagner D.P., Draper E.A., Zimmerman J.E., Bergner M., Bastos P.G., Sirio C.A., Murphy D.J., Lotring T., Damiano A. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest. 100:1991;1619-1636.
21. Hyatt J.M., McKinnon S., Zimmer G.S., Schentag J.J. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin. Pharmacokinet. 28:1995;143-160.
22. Moore R.D., Lietman P.S., Smith C.R. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J. Infect. Dis. 155:1987;93-99.
23. Neu H.C. Pharmacokinectics, microbiology, cost: interrelated problems for the 1990 that impact on the use of fluoroquinolone antimicrobial agents. Am. J. Med. 92:1992;2-7.
24. Schentag J.J., Gilliland K.K., Paladino J.A. What have we learned from pharmacokinetic and pharmacodynamic theories. Clin. Infect. Dis. 32:2001;39-46.
25. Thomas J.K., Forrest A., Bhavnani S.M., Hyatt J.M., Cheng A., Ballow C.H., Schentag J.J. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob. Agents Chemother. 42:1998;521-527.
26. Kashuba A.D., Bertino J.S. Jr., Nafziger A.N. Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by Gram negative organisms. Antimicrob. Agents Chemother. 42:1998;1842-1844.
27. Kashuba A.D., Nafziger A.N., Drusano G.L., Bertino J.S. Jr. Optimizing aminoglycosides therapy for nosocomial pneumonia caused by Gram-negative bacteria. Antimicrob. Agents Chemother. 43:1999;623-629.
28. Begg E.J., Peddie B.A., Chambers S.T., Boswell D.R. Comparison of gentamicine dosing regimens using an in vitro model. J. Antimicrob. Chemother. 29:1992;427-433.
29. Blaser J., Stone B.B., Groner M.C., Zinner S.H. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bacterial activity and emergence of resistance. Antimicrob. Agents Chemother. 31:1987;1054-1060.
30. Drusano G.L., Jonson D.E., Rosen M., Standiford H.C. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob. Agents Chemother. 37:1993;483-490.
31. Dudley M.N. Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones. Am. J. Med. 91:1991;45-50.
32. Dudley M.N., Zinner S.H. Single daily dosing of amikacin in in vitro model. J. Antimicrob. Chemother. 27:1991;15-19.
33. Shibl A.M., Hackbarth C.J., Sande M.A. Evaluation of pefloxacin in experimental Escherichia coli meningitis. Antimicrob. Agents Chemother. 29:1986;409-411.
34. Deziel-Evans L.M., Murphy J.E., Job M.L. Correlation of pharmacokinetic indices with therapeutic outcome in patients receiving aminoglycosides. Clin. Pharmacol. 5:1986;319-324.
35. Turnidge J.D. The pharmacodynamics of β-lactams. Clin. Infect. Dis. 27:1998;10-22.
36. Ackerman B.H., Vannier A.M., Eudy E.B. Analysis of vancomycin time-kill studies with Staphylococcus species by using a curve-stripping program to describe the relationship between concentration and pharmacodynamics response. Antimicrob. Agents Chemother. 36:1992;1766-1769.
37. Craig W.A., Ebert S.C. Killing and regrowth of bacterial in vitro: a review. Scand. J. Infect. Dis. 74:1991;63-70.
38. Roosendaal R., Bakker-Woundenberg I.A., Van den Berg J.C., Michel M.F. Therapeutic efficacy of continuous versus intermittent administration of ceftazidime in an experimental Klebsiella pneumoniae in rats. J. Infect. Dis. 152:1985;373-378.
39. Vogelman B., Craig W.A. Kinetics of antimicrobial activity. J. Pediatr. 108:1986;835-840.
40. Gerber A.U., Brugger H.P., Feller C., Stritzko T., Stalder B. Antibiotic therapy of infections due to Pseudomonas aeruginosa in normal and granulocytopenic mice:comparison of murine and human pharmacokinetics. J. Infect. Dis. 153:1986;90-97.
41. Legget J.E., Fantin B., Ebert S., Totsuka K., Vogelman B., Calame W., Mattie H., Craig W.A. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J. Infect. Dis. 159:1989;281-292.
42. Fagon J.Y., Chastre J., Hance A.J., Montravers P., Novara A., Gibert C. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am. J. Med. 94:1993;281-288.
43. Kollef M.H., Silver P., Murphy D.M., Trovillion E. The effect of late-onset ventilator-associated pneumonia in determining patient mortality. Chest. 108:1995;1655-1662.
44. Torres A., Aznar R., Gatell J.P., Jimenez P., Gonzalez J., Ferrer A., Celis R., Rodriguez-Roisin R. Incidence, risk and prognosis factors of nosocomial pneumonia in mechanically ventilated patients. Am. Rev. Resp. Dis. 142:1990;523-528.